Addition Therapeutics: Funding, Investors & Team (Sep 2026)
Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovative methods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies.
Addition Therapeutics has raised $100M across 1 funding round on record, the most recent a Series A of $100M announced in Dec 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Addition Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2025.
Addition Therapeutics Funding Rounds
Addition Therapeutics Founders and Leadership Team
Contact details for the Addition Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Addition Therapeutics Funding Compared to Other Biotechnology Startups
Addition Therapeutics' latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Addition Therapeutics in Biotechnology and South San Francisco
Companies Similar to Addition Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Addition Therapeutics Funding FAQs
What does Addition Therapeutics do?
Addition Therapeutics focuses on developing RNA-only therapeutics using its proprietary PRINT technology. This approach enables the precise insertion of genetic elements at specific safe harbor sites, aiming to transform the field of genetic medicine. They operate within the biotechnology industry and are backed by venture capital. Their innovative methods target gene editing and regulation, potentially offering new solutions in the field of genetic therapies.
How much funding has Addition Therapeutics raised?
Addition Therapeutics has raised $100M across 1 round on record. The most recent is a Series A of $100M announced in Dec 2025.
When did Addition Therapeutics last raise funding?
Addition Therapeutics' most recent funding round on record is a Series A of $100M, announced in Dec 2025.
Who founded Addition Therapeutics?
FundedIQ lists Kathleen Collins (Founder) at Addition Therapeutics.
Where is Addition Therapeutics headquartered?
Addition Therapeutics is based in South San Francisco, California, United States.
How many employees does Addition Therapeutics have?
Addition Therapeutics is in the 51-100 employee band.
How does Addition Therapeutics' funding compare to other Biotechnology startups?
Addition Therapeutics' latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Addition Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Addition Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.